BACKGROUND: Everolimus is a mammalian target of rapamycin inhibitor approved for the treatment of metastatic renal cell carcinoma (mRCC). We aimed to assess the association between pre-treatment neutrophil-to-lymphocyte ratio (NLR) and the outcome of patients treated with everolimus for mRCC. METHODS: Ninety-seven patients with mRCC were treated with everolimus till April 2013 in our institutions. Patients were stratified in two groups with NLR >3 (Group A) vs <3 (Group B). Progression-free survival (PFS) and overall survival (OS) were estimated using Kaplan-Meier method. Gender, age, Motzer prognostic group, PFS on first-line therapy, neutrophilia and NLR were included in the Cox analysis to investigate their prognostic relevance. RESULTS: Median OS and PFS were 10.6 and 5.3 months, respectively. Median OS was 12.2 months in Group A and 24.4 months in Group B (P=0.001). Median PFS was 3.4 months in Group A and 9.9 months in Group B (P<0.001). At multivariate analysis, only Motzer prognostic group and NLR were independent prognostic factors for OS and PFS. CONCLUSION: Pre-treatment NLR is an independent prognostic factor for patients with mRCC treated with second- or third-line everolimus. This should be investigated and validated in prospective studies

Pre-treatment neutrophil to lymphocyte ratio as an independent prognostic factor in patients with treated with everolimus for metastatic renal cell carcinoma / Santoni, M; De Giorgi, U; Iacovelli, R; Conti, A; Burattini, L; Rossi, L; Luca Burgio, S; Berardi, R; Muzzonigro, G; Cortesi, E; Amadori, D; Cascinu, Stefano. - In: BRITISH JOURNAL OF CANCER. - ISSN 0007-0920. - 109:7(2013), pp. 1755-1759. [10.1038/bjc.2013.522]

Pre-treatment neutrophil to lymphocyte ratio as an independent prognostic factor in patients with treated with everolimus for metastatic renal cell carcinoma

CASCINU, Stefano
2013

Abstract

BACKGROUND: Everolimus is a mammalian target of rapamycin inhibitor approved for the treatment of metastatic renal cell carcinoma (mRCC). We aimed to assess the association between pre-treatment neutrophil-to-lymphocyte ratio (NLR) and the outcome of patients treated with everolimus for mRCC. METHODS: Ninety-seven patients with mRCC were treated with everolimus till April 2013 in our institutions. Patients were stratified in two groups with NLR >3 (Group A) vs <3 (Group B). Progression-free survival (PFS) and overall survival (OS) were estimated using Kaplan-Meier method. Gender, age, Motzer prognostic group, PFS on first-line therapy, neutrophilia and NLR were included in the Cox analysis to investigate their prognostic relevance. RESULTS: Median OS and PFS were 10.6 and 5.3 months, respectively. Median OS was 12.2 months in Group A and 24.4 months in Group B (P=0.001). Median PFS was 3.4 months in Group A and 9.9 months in Group B (P<0.001). At multivariate analysis, only Motzer prognostic group and NLR were independent prognostic factors for OS and PFS. CONCLUSION: Pre-treatment NLR is an independent prognostic factor for patients with mRCC treated with second- or third-line everolimus. This should be investigated and validated in prospective studies
109
7
1755
1759
Pre-treatment neutrophil to lymphocyte ratio as an independent prognostic factor in patients with treated with everolimus for metastatic renal cell carcinoma / Santoni, M; De Giorgi, U; Iacovelli, R; Conti, A; Burattini, L; Rossi, L; Luca Burgio, S; Berardi, R; Muzzonigro, G; Cortesi, E; Amadori, D; Cascinu, Stefano. - In: BRITISH JOURNAL OF CANCER. - ISSN 0007-0920. - 109:7(2013), pp. 1755-1759. [10.1038/bjc.2013.522]
Santoni, M; De Giorgi, U; Iacovelli, R; Conti, A; Burattini, L; Rossi, L; Luca Burgio, S; Berardi, R; Muzzonigro, G; Cortesi, E; Amadori, D; Cascinu, Stefano
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1079143
Citazioni
  • ???jsp.display-item.citation.pmc??? 37
  • Scopus 70
  • ???jsp.display-item.citation.isi??? 72
social impact